Pembrolizumab

BNF:
8.1.5
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

RED1,8: NICE TA357: for treating advanced melanoma after disease progression with ipilimumab(decision date - November 2015)

RED1,8: NICE TA366: for treating advanced melanoma not previously treated with ipilimumab (decision date - December 2015)

RED1,2,3,8: NICE TA428: for treating PDL1-positive non-small-cell lung cancer after chemotherapy (decision date - February 2017)

RED1,2,3,8: NICE TA519: for the treatment of locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (decision date - May 2018)

RED1,2,3,8: NICE TA522: for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (decision date - July 2018)

RED1,2,3,8: NICE TA531: for untreated PD-L1 positive metastatic non-small-cell lung cancer (replaces TA447) (decision date - August 2018)

RED1,2,3,8: NICE TA553: for adjuvant treatment of resected melanoma with high risk of reoccurrence (decision date - January 2019)

RED1,2,3,8: NICE TA557: with pemetrexed and platinum chemotherapy for untreated metastatic, non-squamous non-small-cell lung cancer. (Decision date - Feb 2019)

RED1,2,3,8: NICE TA600: with carboplatin and paclitaxel for untreated metastatic squamous NSCLC. (Decision date - October 2019)

RED1,2,3,8: NICE TA650: with axitinib for untreated advanced renal cell carcinoma. (Decision date - October 2020)

RED1,2,3,8: NICE TA661: for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. (Decision date - December 2020)

DO NOT PRESCRIBE (DNP)6: NICE TA540: for treating relapsed or refractory classical Hodgkin lymphoma (Decision date - October 2018)

DO NOT PRESCRIBE (DNP)6: NICE TA570: for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (Decision date - April 2019)

Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire CCG

Derby and Derbyshire CCG